Extend health and lifespan
Cure chronic pathologies
Beyond human capabilities
Unleash the power of symbiosis
The problem
Today we have already dissected the pathways and cellular mechanisms causing human pathologies and aging-related diseases, we know which proteins or drug can significantly improve these conditions in vitro and in transgenic animal models...
...however the problem is not the therapeutic agent itself, but the therapeutic system used to deliver it to the target host cells.
Administration of the simple therapeutic agent to the patient is usually: inefficient (most of it degrades in extra-cellular environments or it's retained by body barriers like the liver), dirty (the therapeutic agent acts on cells nearby the administration area with no specificity) and needs multiple doses. Modern therapies that target human diseases or aim to extend human lifespan overpass, by some extent, these delivery problems of the therapeutic agent, but they still show several limitations:
-
The delivery efficiency of the therapeutic agent in these systems and need often repeated doses
​​
-
The therapeutic effect is often shorter than one week
​​
-
These systems often cause immune responses or toxicity at repeated doses
​
Below we report alternative approaches to sustained systemic exposure:
Our Technology
As a “therapeutic tattoo” we are using engineered microalgae-based living photosynthetic particles ("Symbiotic particles"). These are injected cutaneously within the host skin and remains in the injection site staying alive for months thanks to the sunlight. The particles continuously secrete over-time low levels of functionalized therapeutic peptides or proteins, that reach the host bloodstream having the desired therapeutic effect.
Progressive cumulative tissue coverage over time
The therapeutic agent is functionalized to penetrate inside host cells with 60-90% of delivery efficiency, however since the symbiotic particles release continuously the therapeutic agent into the bloodstream over time, after a couple of weeks the therapeutic agent will be delivered to every cell of the host body, reaching the >97% of delivery efficiency over time.
Scalable manufacturing with low COGS
The total cost for the symbiotic particles production and for the therapeutic agent functionalization is very low (~200$ per dose). Additionally a single dose of symbiotic particles can release the therapeutic agent for several months, depending on the intended use of the technology, making the system very attractive from an economical prospective.
No toxicity or immune reaction observed
Our preliminary study on animal models show that the symbiotic particles injected under the host skin are biocompatible and don't cause any inflammation over time. Moreover the therapeutic agent is released by the symbiotic particles at constant but low amount over-time, avoiding any cytotoxic effect on the host cells.
Long-acting profile
reduces dosing burden
The symbiotic therapy doesn't require multiple doses to achieve a significant effect on the host. A single injection of symbiotic particles under the skin can last for very long, making the therapy effective on more cells of the host body.
Programmable payloads &
targeting flexibility
The therapeutic agent can be functionalized to act as an hormon, without cells penetration, as an enzyme, with cell penetration, or to target only specific cell populations in the host body. Additionally any protein or peptide may be used as a therapeutic agent just switching the modules before the symbiotic particles are injected under the host skin.
Localized at the injection site and external off-switch (laser)
The symbiotic particles stay localized within the skin underlayers, with no possibility to infiltrate in other tissues. Additionally, in case the patient decides to end the therapy, the symbiotic particles can be removed using laser technologies already developed for tatoos ink removal.
Our Targets
The symbiotic therapy system we developed is suitable in the following contexts:
-
Pathologic treatments
​
-
Lifespan extension
​
-
Safe biohacking
​
​
Our Timeline
News and Updates
18 November 2025
We are proud to announce that Symbiotica Therapeutics has been selected by SPRIND - Bundesagentur für Sprunginnovationen. This milestone represents a significant recognition of the innovative scientific potential of our long-acting symbiotic delivery system. We thank SPRIND for their trust and look forward to a productive collaboration!!
